Teva与Sanofi公布duvakitug在中重度溃疡性结肠炎/克罗恩病2b期长期扩展研究44周疗效维持阳性数据

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension study in patients with moderately-to-severely active ulcerative colitis or Crohn's disease, which demonstrated that duvakitug maintained clinically meaningful efficacy improvements across multiple endpoints over 44 weeks. In ulcerative colitis, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at week 44. In Crohn's disease, duvakitug maintained high rates of endoscopic response, clinical response, and clinical remission at week 44.
Duvakitug is currently under clinical investigation, and efficacy and safety have not been evaluated by any regulatory authority. Sanofi and Teva are collaborating to co-develop and co-commercialize duvakitug for the treatment of ulcerative colitis and Crohn's disease, as well as fibrostenotic Crohn's disease and hidradenitis suppurativa.
In pre-market trading on NYSE, Teva shares are up 0.87 percent to $41.64.
For More Such Health News, visit rttnews.com.
Note: The drug name in the headline and the spelling of Crohn's disease in the article have been corrected.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.